Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.7% - Should You Buy?

Key Points

• Shares of Capricor jumped 9.7% on Monday to about $34.24 on ~1.31M shares traded; the stock trades above its 50‑day and 200‑day moving averages ($28.27 and $20.08) and has a market cap near $1.98B.
• Analysts are largely bullish—nine Buys vs. one Sell—with an average target price of $46.09 and individual targets ranging roughly $50–$62, though one shop recently downgraded to a Sell.
• Insiders have been net sellers recently: executives (including CFO Anthony Bergmann and director Karimah Es Sabar) sold large blocks this quarter (total insider sales 147,529 shares), and insiders now own about 10.5% of the company.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s share price shot up 9.7% on Monday . The company traded as high as $35.99 and last traded at $34.2350. 1,310,929 shares were traded during trading, a decline of 1% from the average session volume of 1,330,564 shares. The stock had previously closed at $31.20.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CAPR. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. UBS Group set a $50.00 price objective on Capricor Therapeutics in a research report on Monday, December 15th. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an "overweight" rating in a research report on Friday, March 13th. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $46.09.

Capricor Therapeutics Price Performance

The business's 50 day moving average is $28.27 and its 200 day moving average is $20.08. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -15.24 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). As a group, analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Anthony Bergmann sold 25,000 shares of the business's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the transaction, the chief financial officer owned 8,223 shares in the company, valued at approximately $247,758.99. The trade was a 75.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Karimah Es Sabar sold 61,265 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 147,529 shares of company stock valued at $4,509,940. Insiders own 10.50% of the company's stock.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently bought and sold shares of the stock. ACT Capital Management LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at $43,000. GoalVest Advisory LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at $59,000. Allworth Financial LP boosted its stake in Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 3,264 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in Capricor Therapeutics in the third quarter valued at $28,000. Finally, State of Wyoming boosted its stake in Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 1,913 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.